Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TELEHEART: Telotristat Ethyl in a Heart Biomarker Study
NCT04810091Phase 3Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- May 2021
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Carcinoid Syndrome (CS) and carcinoid heart disease (CHD) comparing Arm A (telotristat ethyl, SSA) with Arm B (placebo, SSA) (2 arms). Primary endpoint: Percent Change in N-terminal pro B-type natriuretic peptide at 6 months. Started May 2021; status: active, not recruiting.
02
Drugs
telotristat ethyl
03
Conditions
Carcinoid Syndrome (CS)carcinoid heart disease (CHD)
Beyond the preview
Go deeper on NCT04810091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04810091.